🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Hims & Hers health CCO sells over $10m in company stock

Published 06/04/2024, 04:21 PM
HIMS
-

Michael Chi, the Chief Commercial Officer of Hims & Hers Health, Inc. (NYSE:HIMS), has made significant transactions in the company's stock, selling shares worth over $10 million. On May 31 and June 3, Chi sold a total of 484,839 shares for an average price range between $19.3432 and $21.00 per share, netting approximately $10,319,439 from the sales.

In addition to the sales, Chi also acquired 817,280 shares through option exercises at prices ranging from $5.01 to $6.82, amounting to a total of $2,835,473. It is important to note that the option exercises and the subsequent sales reported were made according to a Rule 10b5-1 trading plan, which was adopted by Chi on March 1, 2024.

Investors often monitor insider transactions as they provide insights into executives' perspectives on their company's stock value. In this case, the CCO's transactions may be of particular interest to current and potential shareholders.

Hims & Hers Health, a company specializing in telehealth services, has been a subject of investor attention, especially considering the growing trend towards digital health solutions. The company's stock performance is often watched closely by those interested in the healthcare industry and technology-driven solutions.

For those holding or considering an investment in Hims & Hers Health, the recent insider activity provides additional data to inform their investment decisions. However, it's also crucial to consider a wider range of factors, including the company's financial performance, market trends, and broader economic indicators.

Chi's remaining ownership in the company following these transactions stands at 176,672 shares of Class A Common Stock, indicating continued alignment with the company's performance and shareholder interests.

The details of the transactions have been filed with the Securities and Exchange Commission and are available for public review.

InvestingPro Insights

Amidst the insider trading activity by Michael Chi, the Chief Commercial Officer of Hims & Hers Health, Inc., investors are keen to understand the company's financial health and stock performance. With a market capitalization of approximately $4.47 billion, Hims & Hers Health is a significant player in the telehealth industry. The company's substantial revenue growth, with a 55.65% increase over the last twelve months as of Q1 2024, showcases its rapid expansion in the digital health solutions market.

According to InvestingPro Tips, Hims & Hers Health is expected to see net income growth this year. Additionally, three analysts have revised their earnings estimates upwards for the upcoming period, indicating a positive outlook on the company's profitability. These insights may provide investors with a sense of optimism regarding the company's future financial performance.

InvestingPro Data highlights that the company has experienced a strong return over the last month, with an 81.97% increase in its stock price. Moreover, the company's stock is trading near its 52-week high, at 97.15% of the peak price, reflecting investor confidence and a strong market presence. The significant price uptick over the last six months, which saw a 130.48% total return, further underscores the robust performance of Hims & Hers Health in the market.

For investors looking to delve deeper into the financials and stock performance of Hims & Hers Health, InvestingPro offers additional tips to guide investment decisions. By using the coupon code PRONEWS24, investors can get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking access to valuable insights that could inform their trading strategies.

It's important to note that while insider transactions can offer clues about a company's internal perspectives, a comprehensive analysis should include various other metrics. With 16 more tips available on InvestingPro, investors have ample information to assess the potential risks and rewards associated with Hims & Hers Health.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.